Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer—A Review

Bladder-Sparing Chemoradiotherapy Combined with Immune Checkpoint Inhibition for Locally Advanced Urothelial Bladder Cancer—A Review

Despite current treatment strategies, the 5-year overall survival of muscle-invasive bladder cancer (MIBC) is approximately 50%. Historically, radical cystectomy (RC) with neoadjuvant chemotherapy has been the first-choice treatment for this patient group. Recently, several studies have reported enc...

Full description

Bibliographic Details
Main Authors: Jons W. van Hattum, Ben-Max de Ruiter, Jorg R. Oddens, Maarten C. C. M. Hulshof, Theo M. de Reijke, Adriaan D. Bins
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Cancers
Subjects:
bladder cancer
bladder-sparing treatment
immune checkpoint inhibitors
Online Access:https://www.mdpi.com/2072-6694/14/1/38

Internet

https://www.mdpi.com/2072-6694/14/1/38

Similar Items